Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

NeoStem signs Collaborative Research Agreement with ImmuneRegen BioSciences

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China and ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc., announced today that they have entered into a Collaborative Research Agreement, focused on the development of an advanced, adult human stem cell product.

23 Apr 2010

AB SCIEX to collaborate in disease studies with Samuel Lunenfeld Research Institute of Mount Sinai Hospital

AB SCIEX, a global leader in life science analytical technologies, today announced that it is collaborating with the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, one of the world's leading centers for biomedical research, to improve disease studies. The project is focused on better understanding cancer, diabetes and heart disease by advancing the study of proteins through the use of an emerging mass spectrometry platform currently under development by AB SCIEX.

22 Apr 2010

Vical presents Phase 2 trial results of TransVax CMV vaccine at World Vaccine Congress

Vical Incorporated announced today that the company's TransVax cytomegalovirus vaccine elicited sustained increases in both cellular and antibody immune responses compared with placebo through the final 12-month follow-up in an ongoing Phase 2 trial in hematopoietic cell transplant recipients.

22 Apr 2010

New insight into mechanism regulating early mammalian development

Scientists at the Genome Institute of Singapore (GIS) have recently generated significant single cell expression data crucial for a detailed molecular understanding of mammalian development from fertilization to embryo implantation, a process known as the preimplantation period. The knowledge gained has a direct impact on clinical applications in the areas of regenerative medicine and assisted reproduction.

22 Apr 2010

Resonant activation can be a strategy against bacterial persistence: Virginia Tech biologist

A Virginia Tech biologist proposes to use a physics strategy called resonant activation to nudge dormant bacteria cells into a stage where they will be sensitive to antibiotics.

22 Apr 2010

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data which demonstrate that its Notch1-specific monoclonal antibody is a highly potent inhibitor of Notch1 function in both in vitro and in vivo models. These data were presented today at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

22 Apr 2010

StemCells to initiate second clinical trial of HuCNS-SC human neural stem cells in NCL

StemCells, Inc. announced today that it has submitted a protocol to the FDA for initiation of a second clinical trial of its proprietary HuCNS-SC human neural stem cells in neuronal ceroid lipofuscinosis, which is also often referred to as Batten disease.

22 Apr 2010

ImmunoCellular Therapeutics, UPENN sign research agreement

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today that the Company has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania to support process development and manufacturing in a planned Phase II clinical trial of ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme.

22 Apr 2010

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.

22 Apr 2010

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

Cellular Dynamics International (CDI) today announced that CDI's development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A. Thomson, Ph.D., on induced pluripotent stem cell (iPSCs) technology, have been named to the MIT Technology Review's Annual 10 Emerging Technologies List.

21 Apr 2010

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Alchemia's subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC. The data demonstrates the ability of the Company's HyACT tumour targeting technology to dramatically enhance the killing of cancer stem cells. These cells are highly resistant to treatment with chemotherapeutic drugs and are believed to be responsible for treatment failure and disease recurrence.

21 Apr 2010

MicroStockProfit.com: CUR reports net loss of $5,096,983 for third-quarter of 2009

MicroStockProfit.com announces an investment report featuring Neuralstem Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

21 Apr 2010

CINJ researches identify new drug candidates that inhibits prostate cancer growth

Trying to break down a barrier that prevents effective treatment of prostate cancer, researchers from The Cancer Institute of New Jersey (CINJ) have identified candidate drugs that block a key protein responsible for tumor growth.

21 Apr 2010

ZenBio awarded Phase I SBIR grant to establish novel human cell-based models of NAFLD

ZenBio, Inc. announced that it has been awarded a Phase I SBIR grant to establish novel human cell-based models of non-alcoholic fatty liver disease (NAFLD) that will be useful for basic research and as a potential drug development platform. The project stems from recent efforts at ZenBio, Inc. to develop methods for differentiating adipose tissue derived progenitor cells into hepatocyte-like cells.

21 Apr 2010

Stemedica receives FDA IND approval for ischemic stroke clinical trial using allogeneic stem cells

Stemedica Cell Technologies, Inc., a world leader in stem cell research and manufacturing, announced that the U.S. Food and Drug Administration (FDA) approved an Investigational New Drug (IND) for a clinical trial for ischemic stroke using Stemedica's high potency proprietary allogeneic stem cells (adult human).

21 Apr 2010

NanoString Technologies launches new miRNA assay kits

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced a unique new product for miRNA analysis that includes a multiplexed assay for profiling the human miRNA transcriptome in a single tube. The company introduced the new assay kit, which expands the applications for its nCounter® Analysis System, at the American Association for Cancer Research annual meeting.

From NanoString Technologies 20 Apr 2010

Hematological malignancies conference to provide update on blood-borne cancer

John Theurer Cancer Center at Hackensack University Medical Center will host a hematological malignancies conference for physicians and patients on Friday, April 23 and Saturday, April 24. The event, entitled "Current and Innovative Modalities in the Management of Hematological Malignancies", is part of John Theurer Cancer Center's commitment to provide both healthcare professionals as well as patients with an update on the newest advances in the field of blood-borne cancers.

20 Apr 2010

Boston Biomedical to present updated Phase I study data of BBI608 cancer drug at 101st AACR

Researchers at Boston Biomedical, Inc., are working to develop a novel first-in-class cancer drug that works by targeting the stem like properties of some cancer cells, and so far, results of an ongoing Phase I clinical trial demonstrate early signs of a strong safety profile and clinical activity.

20 Apr 2010

Sigma Life Science announces global release of CompoZr Targeted Integration Kit

Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich®, today announced an extension to its award-winning CompoZr® product offering with the global release of the CompoZr Targeted Integration Kit, AAVS1. This kit provides a powerful method for the controlled transgene integration and expression of any gene in any human cell line using Sigma-Aldrich's proprietary CompoZr Zinc Finger Nuclease (ZFN) technology.

20 Apr 2010

Millipore begins global shipments of Scepter Handheld Automated Cell Counter

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced it has begun full commercial shipments of its Scepter™ Handheld Automated Cell Counter to customers worldwide.

20 Apr 2010

Stem Cells News and Research

Further Reading

NeoStem signs Collaborative Research Agreement with ImmuneRegen BioSciences

AB SCIEX to collaborate in disease studies with Samuel Lunenfeld Research Institute of Mount Sinai Hospital

Vical presents Phase 2 trial results of TransVax CMV vaccine at World Vaccine Congress

New insight into mechanism regulating early mammalian development

Resonant activation can be a strategy against bacterial persistence: Virginia Tech biologist

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

StemCells to initiate second clinical trial of HuCNS-SC human neural stem cells in NCL

ImmunoCellular Therapeutics, UPENN sign research agreement

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

MicroStockProfit.com: CUR reports net loss of $5,096,983 for third-quarter of 2009

CINJ researches identify new drug candidates that inhibits prostate cancer growth

ZenBio awarded Phase I SBIR grant to establish novel human cell-based models of NAFLD

Stemedica receives FDA IND approval for ischemic stroke clinical trial using allogeneic stem cells

NanoString Technologies launches new miRNA assay kits

Hematological malignancies conference to provide update on blood-borne cancer

Boston Biomedical to present updated Phase I study data of BBI608 cancer drug at 101st AACR

Sigma Life Science announces global release of CompoZr Targeted Integration Kit

Millipore begins global shipments of Scepter Handheld Automated Cell Counter

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo